Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of intravitreal THR-317 for macular telangiectasia type 1
2017-004010-26Phase 2Completed
- Sponsor
- Oxurion
- Start
- Jun 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of THR-317 in idiopathic macular telangiectasia type 1 and retinal telangiectasia, sponsored by Oxurion. Primary endpoint: Change from baseline in central subfield thickness (CST). Started Jun 2018; status: completed.
02
Drugs
THR-317
03
Conditions
idiopathic macular telangiectasia type 1retinal telangiectasia
Beyond the preview
Go deeper on 2017-004010-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004010-26.